Skip to content
Alphyn Announces Positive Results from Second Cohort of Phase 2a Clinical Trial in Atopic Dermatitis
Alphyn
Breakthrough Therapies for Skin Diseases
About
What We Do
Leadership & Board
Science & Business Advisory
Platform
AB-101 Multi-Target Therapeutics
Pipeline
Atopic Dermatitis
Epidermolysis Bullosa
News
Press Releases
In the News
Events
Contact Us
About
What We Do
Leadership & Board
Science & Business Advisory
Platform
AB-101 Multi-Target Therapeutics
Pipeline
Atopic Dermatitis
Epidermolysis Bullosa
News
Press Releases
In the News
Events
Contact Us
That page could not be found.
Please search
Alphyn Biologics
below.
Search Alphyn Biologics
Search:
Go to Top